Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading about AbbVie鈥檚 sprawling drug pipeline, patent cliffs, and FDA milestones inside a 300-page 10-K can be daunting. Add tables that track Humira biosimilar erosion and footnotes on Allergan-related intangibles, and even seasoned analysts look for help. That鈥檚 why this page exists鈥�AbbVie SEC filings explained simply, without losing the critical details investors need.
Stock Titan鈥檚 AI breaks down every document the moment it hits EDGAR. Whether you need an AbbVie annual report 10-K simplified for pipeline probability math, an AbbVie quarterly earnings report 10-Q filing summarizing segment sales, or an AbbVie 8-K material events explained after a surprise FDA letter, our platform highlights the numbers and narrative that move ABBV shares. AG真人官方-time alerts surface AbbVie Form 4 insider transactions real-time, turning raw data into context within minutes. The same engine powers deeper AbbVie earnings report filing analysis that links management commentary to model-ready metrics.
Investors often ask how to spot patent-expiration risk or track Botox Aesthetics revenue in SEC disclosures. Here鈥檚 where to look:
- Form 4鈥攎辞苍颈迟辞谤 AbbVie insider trading Form 4 transactions and AbbVie executive stock transactions Form 4 before key drug launches.
- 10-Q / 10-K鈥攃ompare R&D spend vs. pipeline progress with AI-generated heat maps.
- DEF 14A鈥攖丑别 AbbVie proxy statement executive compensation reveals incentives tied to new-drug approvals.
From 鈥渦nderstanding AbbVie SEC documents with AI鈥� to setting custom alerts for upcoming trials, Stock Titan equips you to act on the data, not just read it.
AbbVie filed a Form 144 reporting a proposed sale of 42,370 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,407,068.11. The filing lists the approximate date of sale as 08/12/2025 and shows the shares were acquired by a stock option exercise on 08/12/2025 with payment in cash.
The notice states there were no securities sold in the past three months by the person for whose account the shares are to be sold. The filing includes the total number of shares outstanding as 1,766,558,253, and identifies the executing broker and the class of security as common stock. No additional transaction context or identities are provided in the document.
AbbVie (ABBV) filed a Form 144 reporting proposed sales of common stock through Northern Trust Securities on the NYSE. The notice lists three proposed transactions: 61,500 shares (aggregate market value $12,043,268.25, approx. sale date 08/01/2025), 35,120 shares ($6,828,296.22, 08/04/2025) and 91,600 shares ($19,208,000, 08/04/2025). The filing shows a reported number of outstanding shares of 1,766,558,253.
The document discloses the acquisition history for the securities to be sold, showing they were received as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific grant amounts listed. The filer indicates no securities sold in the past three months and includes the standard Rule 144 attestation about lack of undisclosed material adverse information.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
